| Literature DB >> 35269761 |
Martyna Bayassi-Jakowicka1, Grazyna Lietzau1, Ewelina Czuba1, Cesare Patrone2, Przemysław Kowiański1.
Abstract
Stress and negative emotions evoked by social relationships and working conditions, frequently accompanied by the consumption of addictive substances, and metabolic and/or genetic predispositions, negatively affect brain function. One of the affected structures is nucleus accumbens (NAc). Although its function is commonly known to be associated with brain reward responses and addiction, a growing body of evidence also suggests its role in some mental disorders, such as depression and schizophrenia, as well as neurodegenerative diseases, such as Alzheimer's, Huntington's, and Parkinson's. This may result from disintegration of the extensive connections based on numerous neurotransmitter systems, as well as impairment of some neuroplasticity mechanisms in the NAc. The consequences of NAc lesions are both morphological and functional. They include changes in the NAc's volume, cell number, modifications of the neuronal dendritic tree and dendritic spines, and changes in the number of synapses. Alterations in the synaptic plasticity affect the efficiency of synaptic transmission. Modification of the number and structure of the receptors affects signaling pathways, the content of neuromodulators (e.g., BDNF) and transcription factors (e.g., pCREB, DeltaFosB, NFκB), and gene expression. Interestingly, changes in the NAc often have a different character and intensity compared to the changes observed in the other parts of the basal ganglia, in particular the dorsal striatum. In this review, we highlight the role of the NAc in various pathological processes in the context of its structural and functional damage, impaired connections with the other brain areas cooperating within functional systems, and progression of the pathological processes.Entities:
Keywords: Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; addiction; depression; nucleus accumbens; schizophrenia
Mesh:
Year: 2022 PMID: 35269761 PMCID: PMC8910774 DOI: 10.3390/ijms23052618
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Psychostimulant-induced and related mental illnesses and neurodegenerative diseases changes to the expression and activation level of different neuronal factors in the nucleus accumbens. * inhibition of group I mGluR-mediated potentiation of NMDAR, ** enhancement of excitatory synaptic transmission onto D1R+ neurons, *** long-term changes in AMPAR-dependent synaptic efficacy, **** impairment of NMDAR-dependent long-term potentiation and long-term depression at glutamatergic synapses. Abbreviations: Aß—amyloid ß; ACh—acetylcholine; AChR—acetylcholine receptor; AMPAR—α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptor; BDNF—brain-derived neurotrophic factor; Cdk5—cyclin-dependent kinase 5; DA—dopamine; DARPP-32—cAMP-regulated phosphoprotein 32; D1R—dopamine D1 receptor; D2R—dopamine D2 receptor; D3R—dopamin D3 receptor; GABA—γ-aminobutyric acid; GABAAR γ—aminobutyric acid type A receptor; Glu—glutamate; GluD1R—glutamate delta-1 receptor; GlyR—glycine receptor; HOMER2—Homer scaffolding protein 2; mGluR—metabotropic glutamate receptor; mTOR1—mechanistic target of rapamycin complex 1; NFκB—Nuclear factor kappa B; NMDAR—N-methyl-D-aspartate receptor; Npas4—neuronal PAS domain protein 4; Nptx2—neuronal pentraxin 2; NPY—neuropeptide Y; pCREB—phosphorylated adenosine 3′5′ cyclic monophosphate response element binding protein; Pmepa1—prostate transmembrane protein, androgen induced 1; SOM—somatostatin; TrkB—tropomyosin receptor kinase B; 5-HT—serotonin.